Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

Background: The once-daily oral combination of daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is effective and well tolerated in patients with hepatitis C virus (HCV). However, further field-practice studies are necessary to investigate the effectiveness and safety of the D...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Rodolfo Sacco, Vincenzo Messina, Umberto Vespasiani Gentilucci, Luigi Elio Adinolfi, Antonio Ascione, Giorgio Barbarini, Angelo Barlattani, Giuseppe Cariti, Raffaele Cozzolongo, Basilio Fimiani, Ruggiero Francavilla, Caterina Furlan, Giovanni Garrucciu, Vincenzo Iovinella, Luca Rinaldi, Massimo Marignani, Paola Begini, Valeria Pace Palitti, Adriano M Pellicelli, Gaetano Scifo, Antonio Facciorusso, Luca Giacomelli, Aashni Shah, Gaetano Bertino, Serena Perazzo, Giampaolo Bresci, Antonio Izzi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BioExcel Publishing Ltd 2020-12-01
coleção:	Drugs in Context
Assuntos:	daclatasvir direct-acting antivirals hcv ns5a inhibitors hcv replication complex ribavirin sofosbuvir
Acesso em linha:	https://www.drugsincontext.com/sustained-virological-response-in-patients-with-hcv-treated-with-daclatasvir-sofosbuvir-with-or-without-ribavirin-a-large-field-practice-study
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!